(Bonus Episode) GLP-1: Please Start Low and Go Slow cover art

(Bonus Episode) GLP-1: Please Start Low and Go Slow

(Bonus Episode) GLP-1: Please Start Low and Go Slow

Listen for free

View show details

About this listen

 Everyone’s suddenly “not hungry,” and we have questions. In this episode, we break down GLP-1 medications, the myths, the side effects nobody posts about, and why “start low and go slow” is not a suggestion — it’s a lifestyle.ReferencesAbu-Nejim, H. (2025). Current perspectives on GLP-1 receptor agonists in contemporary therapeutics. Journal of Clinical Medicine, 14(3), 455–468. https://pmc.ncbi.nlm.nih.gov/articles/PMC12511252/Advisory Board. (2026, January 12). The biggest health trends in 2026. https://www.advisory.com/daily-briefing/2026/01/12/health-trendsAssociated Press. (2026, January 14). Food companies target users of weight-loss drugs with “GLP-1 friendly” labels. https://apnews.com/article/5bb5dfaae3778b1968c1793326e8ba73IQVIA. (2026, January). Outlook for obesity in 2026: From consolidation to innovation. https://www.iqvia.com/locations/emea/blogs/2026/01/outlook-for-obesity-in-2026Moiz, A. (2025). The expanding role of GLP-1 receptor agonists. Frontiers in Endocrinology, 16, 112233. https://pmc.ncbi.nlm.nih.gov/articles/PMC12303005/Reiss, A. B. (2025). Weight reduction with GLP-1 agonists and paths for future obesity therapies. International Journal of Obesity, 49(2), 215–224. https://pmc.ncbi.nlm.nih.gov/articles/PMC11940170/Reuters. (2026, January 7). Study finds weight and health issues return after stopping obesity drugs. https://www.reuters.com/business/healthcare-pharmaceuticals/less-than-two-years-after-stopping-obesity-drugs-weight-health-issues-return-2026-01-07/Reuters. (2026, January 14). AbbVie plans to build out its presence in obesity market. https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-plans-build-out-its-presence-obesity-market-2026-01-14/Trujillo, J. M., & Nuffer, W. (2021). GLP-1 receptor agonists: An updated review of head-to-head clinical studies. Therapeutic Advances in Endocrinology and Metabolism, 12, 1–16. https://pmc.ncbi.nlm.nih.gov/articles/PMC7953228/U.S. News & World Report. (2026, January 6). GLP-1 ranks as No. 1 health trend for 2026. https://www.foodbusinessnews.net/articles/29573-glp-1-ranks-as-no-1-health-trend-for-2026World Health Organization. (2025, December 1). WHO issues global guideline on the use of GLP-1 medicines in treating obesity. https://www.who.int/news/item/01-12-2025-who-issues-global-guideline-on-the-use-of-glp-1-medicines-in-treating-obesity#NurseChatDiaries#GLP1#StartLowGoSlow#HealthPodcast#HealthcareTalk#WeightLossMyths#MedicalHumor#HealthEducation#NurseLife#WellnessWithoutJudgment#ozempic
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.